MRKPDUFA
WELIREG/Belzutifan (MK-6482) + LENVIMA/Lenvatinib (E7080) (HIF-2α Combo)
Advanced Clear Cell Renal Cell Carcinoma After PD-1/PD-L1 Therapy
Approval decisionFDA regulatory calendar
Track FDA action dates and advisory committee meetings by month. Each event links to its company, drug, indication and source-backed research record.
FDA regulatory calendar
Advanced Clear Cell Renal Cell Carcinoma After PD-1/PD-L1 Therapy
Approval decisionStage III dMMR Colon Cancer (Adjuvant)
Approval decisionUse the monthly FDA calendar to review PDUFA target dates and advisory committee meetings, then open each event for drug, company, indication and source context.
Activated Phosphoniositide 3-kinase Delta Syndrome (APDS in children 4–11) (label expansion)
Approval decision